Upstate Active Clinical Trials

Study Title:

EA5182: Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

What is the purpose of the study? (in Layman's terms, please describe the study)

-

Upstate Institutional Review Board (IRB) Number:

1816837

Study/Protocol ID:

EA5182

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Stephen L Graziano, MD

What is involved if I participate?

• How long is the study?
  -
• Is transportation provided or reimbursed?
  No
• Is parking provided or reimbursed?
  No
• What tests and procedures are involved?
  -

Where will the study take place?

Upstate Medical University-Hem Onc
Upstate Oneida-HemOnc
Upstate Oswego-HemOnc

Other Information:

-

ClinicalTrials.Gov ID:

NCT04181060

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Raneem Alarawi
Phone: 315-464-6074
Email: [email protected]

Return to Previous Page || Search Again